Articles by Jill Wechsler - Applied Clinical Trials

Articles by Jill Wechsler

FDA reviewers strive to assess new postmarketing programs while also evaluating applications.

Stiffer enforcement of research standards aims to restore the public's confidence in agency actions.

International health crises expand testing of new vaccines and drug treatments for third-world diseases.

Pressure to reduce health care spending puts R&D, costs, and coverage on the negotiating table.

FDA leaders stress innovation and disclosure in promoting the agency's public health mission.

Jill Wechsler provides a special report of a briefing with FDA's new commissioner Margaret Hamburg.

Agency officials and sponsors anticipate stiffer oversight of research operations and disclosure requirements.

Government funding slated to boost studies comparing medications to other treatments.

Biomedical research community finds privacy policies add cost and complexity to clinical studies.

Pharmaceutical & Biotech conferences covering the entire pipeline from discovery to development, trials and marketing Eli Lilly uses SAS® to speed up clinical trials. Read more.	Optimize Your Patient Enrollment with a Global Collaborative Solution Powered with Predictive Analytics CHILTERN, UNDERSTANDING GLOBAL CLINICAL RESEARCH Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET